Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors

March 23, 2020 updated by: BeiGene

A Phase 1A/1B, Open-Label, Multiple-Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Preliminary Antitumor Activities of the B RAF Inhibitor BGB 283 in Subjects With Solid Tumors

This study will evaluate the safety, tolerability, pharmacokinetic profile and treatment effect of a new drug known as BGB-283 in patients with solid tumours.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

131

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • New South Wales
      • Camperdown, New South Wales, Australia, 2050
        • Chris O'Brien Lifehouse
      • Port Macquarie, New South Wales, Australia, 2444
        • North Coast Cancer Institute
      • Randwick, New South Wales, Australia, 2031
        • Prince of Wales Hospital
      • Westmead, New South Wales, Australia, 2145
        • Westmead Hospital
    • Queensland
      • Southport, Queensland, Australia, 4215
        • Tasman Oncology Research Ltd
      • Woolloongabba, Queensland, Australia, 4102
        • Princess Alexandra Hospital
    • South Australia
      • Adelaide, South Australia, Australia, 5000
        • Royal Adelaide Hospital
      • Woodville South, South Australia, Australia, 5011
        • The Queen Elizabeth Hospital
    • Victoria
      • Box Hill, Victoria, Australia, 3128
        • Box Hill Hospital
      • Clayton, Victoria, Australia, 3168
        • Monash Medical Centre
      • Heidelberg, Victoria, Australia
        • Austin Health
      • Malvern, Victoria, Australia, 3144
        • Cabrini Hospital
      • Melbourne, Victoria, Australia, 3004
        • The Alfred Hospital
      • Melbourne, Victoria, Australia
        • Peter Maccallum Cancer Centre
      • Parkville, Victoria, Australia
        • Royal Melbourne Hospital
    • Western Australia
      • Nedlands, Western Australia, Australia, 6009
        • Linear Clinical Research Limited
      • Christchurch, New Zealand, 8011
        • Christchurch Hospital
      • Dunedin, New Zealand, 9106
        • Dunedin Public Hospital
      • Hamilton, New Zealand
        • Waikato Hospital
      • Wellington, New Zealand
        • Wellington Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Provided written informed consent prior to enrollment.
  2. Male or female and at least 18 years of age.
  3. A life expectancy of at least 12 weeks.
  4. Histologically or cytologically confirmed advanced or metastatic solid tumor for which no effective standard therapy is available.
  5. One of B-RAF, N-RAS, or K-RAS mutation positive solid tumor.
  6. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1.
  7. Able to swallow and retain oral medication.
  8. Adequate bone marrow, liver, and renal function:

    • Hemoglobin > 9 g/dL
    • Absolute neutrophil count ≥ 1000/mm^3
    • Platelets ≥ 100,000/mm^3
    • Total bilirubin ≤1.5 times the upper limit of normal (ULN)
    • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN (≤ 5 x ULN for subjects with known liver metastasis)
    • Creatinine clearance ≥ 45 mL/min (calculated by the Cockcroft Gault formula).
  9. Female subjects are eligible to enter and participate in the study if they are of:

    a) Non childbearing potential (i.e., physiologically incapable of becoming pregnant), including any female who

    i) Has had a hysterectomy,

    ii) Has had a bilateral oophorectomy (ovariectomy),

    iii) Has had a bilateral tubal ligation, or

    iv) Is post menopausal (total cessation of menses for ≥ 1 year).

    b) Childbearing potential, has a negative serum pregnancy test at screening (within 7 days of the first investigational product administration), and uses adequate contraception before study entry and throughout the study until 28 days after the last investigational product administration. Adequate contraception, when used consistently and in accordance with both the product label and the instructions of the physician, are defined as follows:

    i) Vasectomized partner who is sterile prior to the female subject's entry and is the sole sexual partner for that female.

    ii) Any intrauterine device with a documented failure rate of less than 1% per year.

    iii) Double barrier contraception defined as condom with spermicidal jelly, foam, suppository, or film; OR diaphragm with spermicide; OR male condom and diaphragm.

  10. Subjects with treated brain metastasis are eligible to enter and participate in the study if they are neurologically stable.

Exclusion Criteria:

  1. Female subjects who are pregnant or lactating.
  2. Subjects receiving cancer therapy (chemotherapy or other systemic anti cancer therapies, immunotherapy, radiation therapy, or surgery) at the time of enrollment.
  3. Any major surgery within 28 days prior to enrollment.
  4. Any radiotherapy within 14 days prior to enrollment, providing the subject has recovered from all toxicities to NCI-CTCAE ≤ Grade 1.
  5. Use of any investigational anti cancer drug within 28 days before the first investigational product administration.
  6. Unresolved toxicity > Grade 1 (according to NCI-CTCAE, Version 4.03) from previous anti cancer therapy, unless agreed by the sponsor.
  7. History or presence of gastrointestinal disease or other condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs.
  8. Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study drug or to any component of BGB-283. (To date there are no known Food and Drug Administration [FDA] approved drugs chemically related to BGB-283).
  9. Untreated leptomeningeal or brain metastasis. Subjects with previously treated brain metastasis that are asymptomatic, off steroids for longer than 28 days are permitted.
  10. Any unstable, pre-existing major medical condition that in the opinion of the Investigator contra indicates the use of an investigational product, including active infection, known human immunodeficiency virus (HIV) positive subjects, or known Hepatitis B or C.
  11. Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol.
  12. As a result of the medical interview, physical examination or screening investigations, the investigator considers the subject unfit for study.
  13. Is on medication listed in the protocol or requires any of these medications during treatment with BGB-283.
  14. Candidates for curative therapy.
  15. Unable or unwilling to comply with the required treatment.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: BGB-283

In the dose escalation part(phase 1a): the dose levels will be escalated following a modified 3+3 dose escalation scheme.

In dose expansion phase(Phase 1b): Patients will be assigned to different groups based on their tumor types

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Number of participants with adverse events in phase 1a
Time Frame: From first dose to within 28 days of last dose of BGB-283, within 1 years in average
From first dose to within 28 days of last dose of BGB-283, within 1 years in average
Objective response rate based on RECIST Version 1.1 in subjects with selected tumor types in phase 1b
Time Frame: From the first administration of the investigational product to the end of the study treatment, within 1 year in average
From the first administration of the investigational product to the end of the study treatment, within 1 year in average

Secondary Outcome Measures

Outcome Measure
Time Frame
Area under the plasma concentration-time curve from time 0 to the time of the last measurable concentration (AUClast) in phase 1a
Time Frame: During first 2 weeks
During first 2 weeks
Area under the plasma concentration-time curve from time 0 to infinity time in (AUC∞) in phase 1a
Time Frame: During first 2 weeks
During first 2 weeks
Maximum plasma concentration (Cmax) in phase 1a
Time Frame: During first 2 weeks
During first 2 weeks
Time to reach maximum plasma concentration (tmax) in phase 1a
Time Frame: During first 2 weeks
During first 2 weeks
Terminal elimination half-life (t1/2) in phase 1a
Time Frame: During first 2 weeks
During first 2 weeks
Tumor response in phase 1a
Time Frame: Every 6 weeks from first dose until the date of first documented progression or date of death from any cause, whichever came first, within 1 year in average
Every 6 weeks from first dose until the date of first documented progression or date of death from any cause, whichever came first, within 1 year in average
Number of participants with adverse events in phase 1b
Time Frame: From first dose to within 28 days of last dose of BGB-283, within 1 year in average
From first dose to within 28 days of last dose of BGB-283, within 1 year in average
Progression-free survival (PFS)
Time Frame: The interval from study treatment initiation until the determination of disease progression or death, within 1 year in average
The interval from study treatment initiation until the determination of disease progression or death, within 1 year in average

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Jayesh Desai, MD, Peter MacCallum Cancer Centre, Australia

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 20, 2013

Primary Completion (Actual)

October 1, 2017

Study Completion (Actual)

October 1, 2017

Study Registration Dates

First Submitted

November 18, 2015

First Submitted That Met QC Criteria

November 18, 2015

First Posted (Estimate)

November 20, 2015

Study Record Updates

Last Update Posted (Actual)

March 25, 2020

Last Update Submitted That Met QC Criteria

March 23, 2020

Last Verified

September 1, 2019

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • BGB-283-AU-001
  • ACTRN12614001176651 (Registry Identifier: The Australian New Zealand Clinical Trials Registry)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Yes

IPD Plan Description

Upon request, and subject to certain criteria, conditions, and exceptions, BeiGene will provide access to individual de-identified participant data from BeiGene-sponsored global interventional clinical studies conducted for medicines for indications that have been approved or in programmes that have been terminated. BeiGene will also consider requests for the protocol, data dictionary, and statistical analysis plan. Data requests can be submitted to medicalinformation@beigene.com.

IPD Sharing Supporting Information Type

  • Study Protocol
  • Statistical Analysis Plan (SAP)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Solid Tumors

Clinical Trials on BGB-283

3
Subscribe